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main adjuvant trastuzumab RCTs and pooled using the ran-
dom-effects model of DerSimonian and Laird. RCT and CP 
patients were compared by using the Cochran Q statistics.
Results Versus RCT patients, CP patients were more 
likely to be older than 50 years (65 vs. 49 %; p < 0.0001) 
and to have HR (ER and/or PgR)-positive (72 vs. 54 %; 
p < 0.0001) BC and less likely to have tumor >2 cm 
(T ≥ 2 cm 39 vs. 59 %; p < 0.0001), positive N (47 vs. 
89 %; p < 0.0001) and a high G (61 vs. 67 %; p = 0.0241). 
CP patients more frequently received adjuvant endocrine 
therapy (70 vs. 57 %; p < 0.0003) and less frequently adju-
vant chemotherapy (97 vs. 99.7 %; p < 0.0001).
Conclusions Most tumor and clinical features differed 
significantly between CP and RCT patients. These data 
Abstract 
Background Several randomized clinical trials (RCTs) 
have demonstrated the efficacy of trastuzumab-based adju-
vant therapy in HER2-positive breast cancer (BC). How-
ever, RCT patients may not invariably be representative of 
patients routinely seen in clinical practice (CP). To address 
this issue, we compared the clinical and tumor features of 
RCT and CP patients with HER2-positive BC.
Patients and methods From January to December 2012, 
650 consecutive patients with HER2-positive early BC, 
treated in 36 different types of Italian healthcare facilities, 
were enrolled in this study. Age, treatment, tumor size (T), 
nodes (N), grade (G), estrogen receptor (ER) and proges-
terone receptor (PgR) status were prospectively collected in 
these CP patients. The same data were extracted from the 
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raise concerns about the applicability of RCT results to CP 
patients.
Keywords Clinical practice · Early breast cancer · 
HER2 · Adjuvant therapy · Trastuzumab
Abbreviations
RCT  Randomized clinical trials
CT  Clinical trials
HER2  Human epidermal growth factor receptor 2
BC  Breast cancer
CP  Clinical practice
ER  Estrogen receptor
PgR  Progesterone receptor
HR  Hormone receptors
T  Tumor size
N  Nodal status
G  Grading
Introduction
The human epidermal growth factor receptor 2 (HER2) gene 
is overexpressed/amplified in 10–25 % (Coussens et al. 1985; 
Slamon et al. 1987, 1989; Perou et al. 2000) of human breast 
cancers (BCs), and in such cases, it is typically associated with 
high biological aggressiveness and a poor prognosis (Slamon 
et al. 1987; Wolff et al. 2007; Curigliano et al. 2009; Gonzalez-
Angulo et al. 2009; Chia et al. 2009). The introduction in clini-
cal practice of effective HER2-targeted therapies has dramati-
cally improved the prognosis of patients with HER2-positive 
disease. Impressive results were obtained in many randomized 
clinical trials (RCTs) in the adjuvant/neoadjuvant and advanced 
setting based on the use of trastuzumab, a monoclonal antibody 
targeted against the external domain of HER2, administered 
in association with, or sequentially to chemotherapy (Slamon 
et al. 2011; Joensuu et al. 2006; Spielmann et al. 2009; Piccart-
Gebhart et al. 2005; Romond et al. 2005; Cobleigh et al. 1999; 
Slamon et al. 2001; Vogel et al. 2002; Seidman et al. 2008; 
Burstein et al. 2007; Robert et al. 2006; Von Minckwitz et al. 
2008). More recently, the RCTs CLEOPATRA (Baselga et al. 
2012) and EMILIA (Verma et al. 2012), which evaluated the 
monoclonal antibodies, pertuzumab and T-DM1, marked a 
positive change in the natural history of metastatic HER2-pos-
itive BC. However, RCTs may not be representative of a “real 
patient population” because patients enrolled in RCTs are usu-
ally free from such comorbidities as hematologic, renal or car-
diac dysfunctions, and are selected for specific tumor features, 
such as tumor size and/or nodal status at diagnosis. For exam-
ple, one of the most important clinical trials with trastuzumab 
in the adjuvant setting, the HERA trial (Piccart-Gebhart et al. 
2005), enrolled only lymph node-positive patients regardless 
of tumor size, or node-negative patients with tumor size larger 
than 1 cm. The issue of the applicability of RCT results to rou-
tine clinical practice is particularly relevant when a treatment 
such as trastuzumab is given to almost all patients with HER2-
positive early BC (EBC).
In this study, we evaluated differences, in terms of clini-
cal and tumor characteristics and comorbidities, between 
RCT patients and patients routinely seen in clinical practice 
not enrolled in clinical trials, to assess whether the popu-
lations enrolled in RCTs are sufficiently representative of 
the general EBC population, and, importantly, to determine 




This was a prospective multicenter observational study. 
Thirty-six different types of Italian healthcare facili-
ties, representative of the entire Italian healthcare sys-
tem, participated in the study. Clinical and demographic 
patient data were centrally collected from each participant 
institution in an anonymous online database designed by 
C.R.T. S.r.l. (Salerno, Italy), accessible only to accred-
ited study participants. Our data were then compared with 
those obtained from the main adjuvant trastuzumab RCTs, 
namely FNCLCC-PACS-04, BCIRG-006, FinHER, 
HERA and NSABP B31-NCCTG N9831. No patient 
identifiers were provided to the authors. The study design 
and informed consent were approved by the ethic com-
mittees of each participant center (IRB protocol number 
for Coordinating Center: 144/12). All patients signed an 
appropriate informed consent concerning aim and design 
of the study and allowed to publish relevant data in anon-
ymous form.
Population characteristics
A total of 650 consecutive patients with HER2-positive 
EBC treated at the participant institutions from January to 
December 2012 were enrolled in the study. Age, menopau-
sal status, treatment information, tumor size (T), axillary 
nodal status (N), grade (G), histotype, estrogen receptor 
(ER), progesterone receptor (PgR) and cumulative hor-
mone receptor (HR) status were prospectively collected 
in clinical practice (CP) patients. Our patients were not 
enrolled in an RCT not because they failed to meet entry 
criteria, but simply because no RCT was ongoing in any of 
the participating centers.
In parallel, the same data were extracted, where possible, 
from the adjuvant trastuzumab RCTs, FNCLCC-PACS-04, 
BCIRG-006, FinHER, HERA and NSABP B31-NCCTG 
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N9831 (total number of patients: 11,414). Tumor grading was 
not reported in the BCIRG-006 trial, and histologic subtype 
was reported only in the FinHER and FNCLCC-PACS04 tri-
als. Quantitative data on ER and PgR expression were missing 
from the FNCLCC-PACS04, BCIRG-006 and HERA trials. 
In these three trials, data on HR status were reported as ER 
and/or PgR positivity/negativity; therefore, we considered the 
cumulative HR status. HER2 positivity was determined locally 
and defined as immunohistochemical staining intensity of 3+ 
or 2+ with evidence of gene amplification at fluorescence 
in situ hybridization. The polyclonal antibody A0485 (Dako, 
Milan, Italy) was used for HER2 immunostaining. HER2 
immunohistochemistry positivity was determined according 
to the American Society of Clinical Oncology—College of 
American Pathologists guidelines (Wolff et al. 2007).
Statistical analyses
A meta-analytical approach was undertaken to compare the 
distribution of the clinical and demographical characteristics 
of women enrolled in clinical trials and those treated in clini-
cal practice. In particular, the clinical and demographic char-
acteristics extracted from RCTs were initially pooled using the 
random-effects model of DerSimonian and Laird (1986). In 
this step, to correct over-dispersion, the raw proportions were 
converted using the Freeman–Tukey transformation and back-
transformed after quantitative data synthesis (Freeman and 
Tukey 1950; Miller 1978). Although in some cases the degree 
of heterogeneity, as estimated by the I2 statistics, was low, we 
decided to use the random-effect model for all the character-
istics because it produced the most conservative estimates. 
Subsequently, a subgroup analysis (clinical trials vs. clinical 
practice) was carried out using the Cochran Q statistics (Deeks 
et al. 2003) as omnibus test, to explore whether the clinical and 
demographical characteristics of patients differ between the 
two groups. Results are presented in forest plots where the dif-
ferent characteristics examined are reported according to sub-
group. Ninety-five percent CI were computed for individual 
studies (using the exact binomial method) and for the pooled 
estimate of clinical trials (according, as previously stated, to a 
random-effect model). All analyses were performed with R sta-
tistics (version 3.2.0), using the additional packages META e 
METAFOR. The significance level was set at p < 0.05.
Results
Demographic, clinical and biological characteristics 
of clinical practice patients
A total of 650 CP patients with HER2-positive EBC 
were enrolled in this study. Table 1 shows patients’ clini-
cal characteristics and adjuvant therapies in our dataset 
and in published clinical trials. In our dataset, median age 
was 55 years (range 27–93 years); 34 % (255) of patients 
were pre-menopausal and 65 % (396) were postmeno-
pausal. Data on adjuvant chemotherapy was available for 
553 patients. Most patients (97 %, 535) received adjuvant 
therapy, and the most frequently delivered chemotherapies 
were anthracyclines (12 %, 66 patients), taxanes (17 %, 93 
patients) or combined treatment with anthracyclines fol-
lowed by taxanes (68 %, 363 patients). Data on endocrine 
therapy were available for 548 patients, and most of them 
(70 %, 381 patients) received adjuvant hormone therapy. 
Data on trastuzumab adjuvant therapy were reported for 
554 patients. Almost all CP patients (98 %, 542 patients) 
received adjuvant trastuzumab at least once.
The biological tumor characteristics in our dataset and 
published RCTs are reported in Table 2. In CP patients, 
91 % (587) of EBCs were invasive ductal carcinomas, 3 % 
(22) were invasive lobular carcinomas, and 4 % (28) were 
other minor subtypes. Fifty-seven percent (369) of CP 
EBCs were poorly differentiated (G3). Overall, 59 % (387) 
of CP tumors were smaller than 2 cm, and 41 % (247) were 
larger than 2 cm. Moreover, 48 % (313) of CP tumors were 
free of lymph node metastases, 28 % (180) were associated 
with fewer than three metastatic nodes, and 15 % (101) 
had more than three metastatic nodes. Seventy-two percent 
(466) of CP EBCs were HR positive (ER positive and/or 
PgR positive); in detail, 70 % (458) were ER positive and 
60 % (391) were PgR positive. All (650) CP EBCs were 
HER2 positive, as expected.
Comparison between CP patients  
and the RCT population
Compared to RCT women, CP patients were more likely to 
be older than 50 years (65 vs. 49 %; Q = 64.31, p < 0.0001; 
Fig. 1a) and to have a smaller tumor (tumor size ≥2 cm 39 
vs. 59 %; Q = 72.08, p < 0.0001; Fig. 1b). They were less 
likely to have metastatic axillary nodes (metastatic nodes 
rate 47 vs. 89 %; Q = 16.56, p < 0.0001; Fig. 1c) and more 
likely to have a lower tumor grade (G3 rate 61 vs. 67 %; 
Q = 5.09, p = 0.0241; Fig. 1d). Overall, CP EBCs were 
more likely to be HR positive than the RCT counterpart 
(72 vs. 54 %; Q = 67.62, p < 0.0001; Fig. 2a). In detail, 
71 % of CP tumors were ER positive versus 51 % of RCT 
tumors (Q = 77.97, p < 0.0001; Fig. 2b), whereas 60 % of 
CP tumors were PgR positive versus 39 % of RCT tumors 
(Q = 92.75, p < 0.0001; Fig. 2c). Neither tumor histotype 
nor menopausal status differed between the two groups.
Figure 3a–c shows the therapeutic strategies used in 
the two study groups. Clinical practice patients more fre-
quently received adjuvant endocrine therapy (70 vs. 57 %, 
Q = 13.17, p < 0.0003; Fig. 3a) and slightly less fre-
quently adjuvant chemotherapy (97 vs. 99.7 %; Q = 22.16, 
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p < 0.0001; Fig. 3b) compared to RCT patients. Among 
chemo-treated patients, there was no difference in the 
type of drugs delivered. Surprisingly, our patients received 
at least one dose of trastuzumab slightly more frequently 
than RCT patients (100 vs. 96.49 %; Q = 9.04, p = 0.024; 
Fig. 3c).
Patients with hematologic and/or neurologic, hepatic, 
renal or cardiac disorders (such as myocardial infarction, 
severe uncontrolled arrhythmias and/or arrhythmias 
requiring regular therapy, poorly controlled hyperten-
sion, congestive heart failure and other significant ill-
nesses) were not eligible for adjuvant RCT (Joensuu 
et al. 2006; Piccart-Gebhart et al. 2005; Romond et al. 
2005; Slamon et al. 2011; Spielmann et al. 2009). On the 
contrary, as shown in Table 3, 43 % (271) of CP patients 
had comorbidities before starting adjuvant treatment: 
Table 1  Population characteristics
CP clinical practice, N/A not available, CT chemotherapy, HT hormonal therapy, w/o without
a In the FinHER trial, the overall population enrolled accounted for 1010 patients, but only 232 of them are HER2 positive and are randomly 
assigned to either receive or not adjuvant trastuzumab. HT data are only reported for the overall population in the original paper
Characteristics BCIRG-006 FinHER FNCLCC-PACS 04 HERA NSABP B31 NCCTG N9831 CP population
N (%) N (%) N (%) N (%) N (%) N (%) N (%)
3222 (100) 1010 (100)−232 
(100)a
528 (100) 3387 (100) 2101 (100) 1944 (100) 650 (100)
Age
Median (years) N/A 50.9 48 49 N/A N/A 55
<50 1698 (53) N/A N/A 1741 (51) 1060 (50) 966 (50) 225 (34)
≥50 1524 (47) N/A N/A 1646 (49) 1041 (50) 978 (50) 421 (65)
Missing 0 (0) N/A N/A 0 (0) 0 (0) 0 (0) 4 (1)
Menopausal status
Premenopausal N/A N/A 226 (43) 533 (16) N/A N/A 255 (39)
Postmenopausal N/A N/A 177 (33) 1576 (46) N/A N/A 395 (61)
Missing/uncertain N/A N/A 125 (24) 1278 (38) N/A N/A 0 (0)
CT adjuvant (CP N = 553)
Yes 3222 (100) 232 (100) 528 (100) 3387 (100) 4006 (99) 535 (97)
No 0 (0) 0 (0) 0 (0) 0 (0) 39 (1) 18 (3)
Missing 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
CT Regimen (CP N = 535)
Anthracyclines w/o 
taxanes
0 (0) 120 (52) 279 (53) 2307 (67) 0 (0) 66 (12)
Taxanes w/o anthracy-
clines
1075 (33) 0 (0) 0 (0) 206 (6) 0 (0) 93 (17)
Anthracyclines  
+ taxanes
2147 (67) 112 (48) 249 (47) 873 (26) 4006 (100) 363 (68)
Other 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 9 (2)
Missing 0 (0) 0 (0) 0 (0) 1 (0) 0 (0) 4 (1)
HT adjuvant (CP N = 548)
Yes 1614 (50) 732 (73) 315 (60) 1710 (50) 1176 (56) 994 (51) 381 (70)
No 1608 (50) 278 (27) 213 (40) 1677 (50) 925 (44) 931 (48) 167 (30)
Missing 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 19 (1) 0 (0)
Trastuzumab adjuvant, as planned (CP N = 554)
Yes 2149 (67) 116 (50) 260 (49) 1694 (50) 2028 (50) 542 (98)
No 1073 (33) 116 (50) 268 (51) 1693 (50) 2017 (50) 12 (2)
Missing 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Trastuzumab adjuvant, at least one time (CP N = 542)
Yes 2126 (99) 115 (99) 234 (90) 1680 (99) 1845 (91) 542 (100)
No 23 (1) 1 (1) 26 (10) 20 (1) 183 (9) 0 (0)
Missing 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
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20 % of CP patients were affected by diverse cardiac 
disorders (7 % had arrhythmias, 5 % had congestive 
heart failure, 2 % had a history of myocardial infarction 
and 86 % had hypertension), 4 % had a neurologic dis-
order, and 4 % were affected by diabetes and 13 % by 
other illnesses.
Discussion
Our study provides evidence that most tumor and clinical 
characteristics differ significantly between CP and RCT 
patients. In particular, CP patients were older and had 
smaller, better differentiated and less advanced tumors 
Table 2  Tumor features
CP clinical practice, T tumor size, N nodal status, ER estrogen receptor, PgR progesterone receptor, HR hormone receptors
Features BCIRG-006 FinHER FNCLCC–PACS 04 HERA NSABP B31 NCCTG N9831 CP population
N (%) N (%) N (%) N (%) N (%) N (%) N (%)
3222 (100) 232 (100) 528 (100) 3387 (100) 2101 (100) 1944 (100) 650 (100)
Histotype
Ductal N/A 209 (90) 495 (94) N/A N/A N/A 587 (91)
Lobular N/A 21 (9) 18 (3) N/A N/A N/A 22 (3)
Other N/A 2 (1) 14 (3) N/A N/A N/A 28 (4)
Missing N/A 0 (0) 1 (0) N/A N/A N/A 13 (2)
Grade
1–2 N/A 77 (33) 181 (34) 1187 (35) 652 (31) 539 (28) 238 (37)
3 N/A 150 (65) 343 (65) 2027 (60) 1407 (67) 1377 (71) 369 (57)
Missing N/A 5 (2) 4 (1) 173 (5) 42 (2) 28 (1) 43 (6)
Ki67
≤20 % N/A N/A N/A N/A N/A N/A 152 (23)
>20 % N/A N/A N/A N/A N/A N/A 467 (72)
Missing N/A N/A N/A N/A N/A N/A 31 (5)
T
1 1283 (40) 81 (35) 235 (45) 1347 (40) 823 (39) 762 (39) 387 (59)
≥2 1936 (60) 150 (65) 285 (54) 1651 (49) 1246 (59) 1181 (61) 247 (38)
Missing 3 (0) 1 (0) 8 (1) 389 (11) 32 (2) 1 (0) 16 (3)
N
0 922 (29) 37 (16) 0 (0) 1100 (32) 0 (0) 282 (14) 313 (48)
1–3 1238 (38) 122 (53) 307 (58) 972 (29) 1212 (58) 932 (48) 180 (28)
≥4 1062 (33) 73 (31) 221 (42) 953 (28) 889 (42) 729 (38) 101 (15)
Missing 0 (0) 0 (0) 0 (0) 362 (11) 0 (0) 1 (0) 56 (9)
ER
Positive N/A 109 (47) N/A N/A 1096 (52) 983 (51) 458 (70)
Negative N/A 123 (53) N/A N/A 987 (47) 960 (49) 191 (29)
Missing N/A 0 (0) N/A N/A 18 (1) 1 (0) 1 (1)
PgR
Positive N/A 79 (34) N/A N/A 832 (40) 752 (39) 391 (60)
Negative N/A 153 (66) N/A N/A 1248 (59) 1188 (61) 257 (40)
Missing N/A 0 (0) N/A N/A 21 (1) 4 (0) 2 (0)
HR
Positive (ER+ and/or PgR+) 1733 (54) 109 (47) 315 (60) 1710 (51) 1176 (56) 994 (51) 466 (72)
Negative (ER− and PgR−) 1489 (46) 123 (53) 213 (40) 1615 (48) 907 (43) 950 (49) 182 (28)
Missing 0 (0) 0 (0) 0 (0) 62 (2) 18 (1) 0 (0) 2 (0)
HER2
Positive 3222 (100) 232 (100) 526 (100) 3387 (100) 2101 (100) 1944 (100) 650 (100)
Negative 0 (0) 0 (0) 2 (0) 0 (0) 0 (0) 0 (0) 0 (0)
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Fig. 1  Age, T, N and G com-
parison between CP and CT 
populations
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because they had fewer metastatic axillary nodes. Impor-
tantly, CP tumors were more endocrine sensitive than RCT 
tumors. Moreover, patients enrolled in RCTs had virtually 
no comorbidities because many of the latter were among 
the RCT exclusion criteria. On the contrary, most of our 
CP patients had health problems, mainly cardiac disorders, 
before cancer diagnosis. However, comorbidities, even 
cardiovascular disorders, did not preclude the use of trastu-
zumab in CP patients. Indeed, the rate of patients receiving 
at least one dose of trastuzumab was higher in CP patients 
than in RCT patients.
Undeniably, trastuzumab has changed the natural his-
tory of HER2-positive BC. Given the biological rationale 
of its mechanism of action and the extraordinary results 
Fig. 2  Hormonal receptor status comparison between CP and CT populations
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in both the preclinical (Baselga and Mendelsohn 1994; 
Baselga et al. 1998; Konecny et al. 2001; Pegram et al. 
1998, 1999, 2000; Roche 2001) and clinical setting (Joen-
suu et al. 2006; Slamon et al. 2011; Spielmann et al. 2009; 
Piccart-Gebhart et al. 2005; Romond et al. 2005; Cobleigh 
et al. 1999; Slamon et al. 2001; Vogel et al. 2002; Sei-
dman et al. 2008; Burstein et al. 2007; Robert et al. 2006; 
Von Minckwitz et al. 2008), the efficacy of trastuzumab is 
no longer questionable. However, we should not take it for 
granted that the safety and tolerability of this anticancer 
Fig. 3  Adjuvant therapeutic strategies compared between CP and CT populations
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treatment in unselected CP patients are the same as that 
observed in RCT patients. Indeed, our study indicates that 
CP and RCT patients differ significantly in terms of tumor 
biology and clinical characteristics, most notably age and 
comorbidities. Because of these differences, the toler-
ability and safety profile of trastuzumab may also differ 
between the CP and RCT settings.
We did not include in our evaluation more recent RCTs 
exploring the use of combined anti-HER2 agents (Piccart-
Gebhart et al. 2014; Pivot et al. 2013) because we focused 
on the use of trastuzumab as a single anti-HER2 agent in 
the adjuvant setting. We cannot exclude that the patients 
enrolled in these more recent studies are more similar to 
those we observed in the present analysis. Interestingly, our 
data also suggest that trastuzumab is much more frequently 
administered in CP than would be expected from a simple 
extrapolation of RCT data, because in “real life”, oncolo-
gists are prone to start trastuzumab even when patients 
have comorbidities.
Conclusions
In conclusion, our data suggest that the efficacy and toler-
ability of therapies should be assessed also in a clinical sce-
nario closer to routine CP to further validate RCT results 
and to understand how well an anticancer agent works in a 
less restricted setting when it’s more widely used.
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